TABLE III.
Patient Outcome
| Subject Number |
Age (years) |
Diagnosis | # days of therapy | DLT | Response | Note |
|---|---|---|---|---|---|---|
| 1 | 9.6 | T cell | 6 | IE* | PD | |
| 2 | 9.4 | B-precursor | 28 | No | SD | |
| 3 | 5.2 | B-precursor | 4 | IE* | - | Found to have Ph+ ALL |
| 4 | 6.8 | B-precursor | 28 | No | CR | |
| 5 | 20.8 | T cell | 45 | No | SD | |
| 6 | 15.2 | B-precursor | 42 | No | SD | |
| 7 | 11.0 | B-precursor | 29 | No | SD | |
| 8 | 7.2 | B-precursor | 25 | No | PD | |
| 9 | 8.0 | B-precursor | 1 | Yes | - | Grade 4 infusion related toxicity lasting > 24 hrs |
| 10 | 3.2 | T cell | 1 | Yes | - | Grade 3 infusion related toxicity. Family withdrew |
| 11 | 7.2 | B-precursor | 4 | IE* | - | Incorrect doses administered |
| 12 | 4.4 | B-precursor | 25 | No | PD | |
| 13 | 9.2 | B-precursor | 18 | IE* | PD |
*
Patient not fully evaluable for toxicity if they received less than 85 % of the intended dose; IE, inevaluable; CR, complete remission; SD, stable disease; PD, progressive disease.